OncLive®: How would you characterize the significance of the ALLIANCE, ECOG E1912, and iLLUMINATE trials within the broader treatment spectrum for chronic lymphocytic leukemia (CLL)? Davids:
Matthew S. Davids, MD, MMSc
At a high-level, it was an exciting opportunity, because we had 3 large randomized trials reading out at the same time, and all 3 looked different CLL patient populations. ECOG19121
for younger patients, ALLIANCE2
for more typical older patients, and iLLUMINATE,3
with an older, frailer population.
The comparative arms for the trials were appropriate standards of care: for the young patients it was FCR [fludarabine, cyclophosphamide, and rituximab], for the middle group of patients it was bendamustine (BR), and then for the older, frailer patients it was chlorambucil with obinutuzumab.
... to read the full story